Strive, Inc. Announces Third Quarter 2025 Financial Results

Strive, Inc. Announces Third Quarter 2025 Financial Results Strive, Inc. Announces Third Quarter 2025 Financial Results GlobeNewswire November 14, 2025

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST) (“Strive” or the “Company”), the first Bitcoin treasury company amplified exclusively with perpetual preferred equity, today announced its financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Highlights:

“In the third quarter, Strive achieved significant milestones in its Bitcoin accumulation journey, including the close of our reverse acquisition of Asset Entities Inc., which resulted in Strive becoming the first publicly traded Bitcoin treasury asset management firm. Strive concurrently closed on a PIPE financing transaction, and deployed the majority of the net proceeds into Bitcoin investments. We also entered into an agreement and plan of merger to acquire Semler Scientific, Inc., which we expect will be accretive to the Bitcoin exposure to our shareholders and provide significant potential future value based on the synergy of Semler's medical device business and the expertise of Strive management and board members. Strive continued this positive momentum into the fourth quarter, closing the successful IPO of its first issuance of variable rate perpetual preferred stock, making Strive the first Bitcoin treasury company to finance its Bitcoin amplification exclusively through perpetual preferred equity, and the second overall, after Strategy, to issue a publicly traded perpetual preferred equity security,” said Matthew Cole, Chairman & Chief Executive Officer of Strive, Inc.

   
(1) Non-GAAP adjusted net loss and non-GAAP adjusted net loss per diluted share are non-GAAP measures. See below for reconciliations of these non-GAAP financial measures to the most comparable GAAP financial measures.


     
STRIVE, INC.
CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
(in thousands, except share and per share data)
     
 September 30,
2025
  December 31,
2024
 (Successor)  (Predecessor)
 (unaudited)  (audited)
Assets:    
Current assets:    
Cash and cash equivalents$109,069   $6,155 
Short-term investments     16,755 
Prepaid expenses 3,533    351 
Other current assets 1,601    500 
Total current assets 114,203    23,761 
Digital assets, at fair value 672,913     
Property and equipment, net 816    951 
Intangible assets, net 361    187 
Right-of-use lease assets 4,141    1,786 
Other non-current assets 142    1,512 
Total assets$792,576   $28,197 
     
Liabilities:    
Current liabilities:    
Compensation and benefits payable$357   $1,112 
Accounts payable and other liabilities 9,186    2,227 
Total current liabilities 9,543    3,339 
Operating lease liabilities 3,604    1,516 
Total liabilities 13,147    4,855 
     
Stockholders’ equity:    
Predecessor preferred stock, $0.00001 par value; 0 and 1,161,650 shares authorized, 0 and 1,158,802 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively     72,488 
Predecessor Class A common stock, $0.00001 par value; 0 and 2,000,000 shares authorized, 0 and 2,000,000 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively      
Predecessor Class B common stock, $0.00001 par value; 0 and 2,339,765 shares authorized, 0 and 400,970 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively      
Successor Class A common stock, $0.001 par value; 444,000,000,000 and 0 shares authorized, 448,817,597 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 449     
Successor Class B common stock, $0.001 par value; 21,000,000,000 and 0 shares authorized, 218,035,473 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 218     
Additional paid-in capital 1,047,185     
Accumulated deficit (268,423)   (49,146)
Total stockholders’ equity 779,429    23,342 
Total liabilities and stockholders' equity$792,576   $28,197 


     
STRIVE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
     
 Successor  Predecessor
 Period from September 12, 2025 to September 30, 2025  Period from July 1, 2025 to September 11, 2025 Three Months Ended September 30, 2024
Revenues:      
Investment advisory fees$246   $1,283  $950 
Other revenue 9    5   34 
Total revenues 255    1,288   984 
       
Operating expenses:      
Fund management and administration 282    1,251   1,272 
Employee compensation and benefits 18,720    3,151   2,182 
General and administrative expense 445    871   4,404 
Marketing and advertising 18    68   89 
Depreciation and amortization 12    43   47 
Total operating expenses 19,477    5,384   7,994 
       
Investment gains/(losses):      
Net unrealized loss on digital assets (10,133)       
Other derivative loss (14,731)       
Net investment gains/(losses) (24,864)       
       
Net operating loss (44,086)   (4,096)  (7,010)
       
Other income/(expense):      
Other income 68    10   208 
Transaction costs (7,484)   (10,280)   
Goodwill and intangible asset impairment (140,785)       
Total other income/(expense) (148,201)   (10,270)  208 
       
Net loss before income taxes (192,287)   (14,366)  (6,802)
Income tax benefit/(expense)         
Net loss$(192,287)  $(14,366) $(6,802)
       
Weighted average number of common shares outstanding:      
Basic(1) 872,349,183    2,325,783   2,225,816 
Diluted(1) 872,349,183    2,325,783   2,225,816 
       
Net loss per common share:      
Basic(1)$(0.22)  $(6.18) $(3.06)
Diluted(1)$(0.22)  $(6.18) $(3.06)
(1) Basic and diluted earnings per common share for Class A and Class B common stock are the same.


     
STRIVE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
     
 Successor  Predecessor
 Period from September 12, 2025 to September 30, 2025  Period from January 1, 2025 to September 11, 2025 Nine Months Ended September 30, 2024
Revenues:      
Investment advisory fees$246   $4,187  $2,560 
Other revenue 9    35   55 
Total revenues 255    4,222   2,615 
       
Operating expenses:      
Fund management and administration 282    4,250   3,488 
Employee compensation and benefits 18,720    7,222   6,465 
General and administrative expense 445    4,229   10,040 
Marketing and advertising 18    231   443 
Depreciation and amortization 12    149   141 
Total operating expenses 19,477    16,081   20,577 
       
Investment gains/(losses):      
Net unrealized loss on digital assets (10,133)       
Other derivative loss (14,731)       
Net investment gains/(losses) (24,864)       
       
Net operating loss (44,086)   (11,859)  (17,962)
       
Other income/(expense):      
Other income 68    586   500 
Transaction costs (7,484)   (15,717)   
Goodwill and intangible asset impairment (140,785)       
Total other income/(expense) (148,201)   (15,131)  500 
       
Net loss before income taxes (192,287)   (26,990)  (17,462)
Income tax benefit/(expense)         
Net loss$(192,287)  $(26,990) $(17,462)
       
Weighted average number of common shares outstanding:      
Basic(1) 872,349,183    2,299,243   2,200,848 
Diluted(1) 872,349,183    2,299,243   2,200,848 
       
Net loss per common share:      
Basic(1) (0.22)   (11.74)  (7.93)
Diluted(1) (0.22)   (11.74)  (7.93)
(1) Basic and diluted earnings per common share for Class A and Class B common stock are the same.


Non-GAAP Financial Measures

This press release contains certain non-GAAP financial measures, consisting of non-GAAP adjusted net income (loss) and non-GAAP adjusted net income (loss) per diluted common share. Non-GAAP financial measures are subject to material limitations as they are not measurements prepared in accordance with GAAP, and are not a substitute for such measurements. Our non-GAAP financial measures are not meant to be considered in isolation and should be read only in conjunction with our consolidated financial statements, which have been prepared in accordance with GAAP. We rely primarily on such consolidated financial statements to understand, manage, and evaluate our business performance and use the non-GAAP financial measures as supplemental information. Reconciliations of reported GAAP historical measures to adjusted non-GAAP measures are included in the financial schedules contained in this press release.

Non-GAAP adjusted net income (loss)

Non-GAAP adjusted net income (loss) and the related non-GAAP adjusted net income (loss) per diluted common share excludes the impact of (i) share-based compensation expense, (ii) depreciation and amortization, (iii) other derivative loss, (iv) transaction costs, and (v) goodwill and intangible asset impairments. We believe these measures offer management and investors insight as they exclude significant non-cash and/or non-recurring items. The following provides GAAP measures of net loss and net loss per diluted common share and the details with respect to reconciling the line items to non-GAAP adjusted net income (loss) and non-GAAP adjusted net income (loss) per diluted common share (all amounts in thousands, other than share and per share information):

 Successor  Predecessor
 Period from September 12, 2025 to September 30, 2025  Period from July 1, 2025 to September 11, 2025 Three Months Ended September 30, 2024
Net loss$(192,287)  $(14,366) $(6,802)
Share-based compensation expense 16,294        
Depreciation and amortization 12    43   47 
Other derivative loss 14,731        
Transaction costs 7,484    10,280    
Goodwill and intangible asset impairment 140,785        
Non-GAAP adjusted net income (loss)$(12,981)  $(4,043) $(6,755)
       
Weighted average number of diluted common shares outstanding 872,349,183    2,325,783   2,225,816 
Net loss per diluted common share$(0.22)  $(6.18) $(3.06)
Non-GAAP adjusted net income (loss) per diluted common share$(0.01)  $(1.74) $(3.03)
       
 Successor  Predecessor
 Period from September 12, 2025 to September 30, 2025  Period from January 1, 2025 to September 11, 2025 Nine Months Ended September 30, 2024
Net loss$(192,287)  $(26,990) $(17,462)
Share-based compensation expense 16,294        
Depreciation and amortization 12    149   141 
Other derivative loss 14,731        
Transaction costs 7,484    15,717    
Goodwill and intangible asset impairment 140,785        
Non-GAAP adjusted net income (loss)$(12,981)  $(11,124) $(17,321)
       
Weighted average number of diluted common shares outstanding 872,349,183    2,299,243   2,200,848 
Net loss per diluted common share$(0.22)  $(11.74) $(7.93)
Non-GAAP adjusted net income (loss) per diluted common share$(0.01)  $(4.84) $(7.87)


About Strive

Strive, Inc. is a bitcoin treasury company. With Bitcoin as its hurdle rate, the Company is focused on (i) maximizing value for shareholders; (ii) accumulating bitcoin; and (iii) outperforming bitcoin over the long run.

Strive's wholly owned subsidiary, Strive Asset Management, is a SEC-registered investment adviser. The Company also owns and operates True North, a Bitcoin-focused media platform.

Learn more at strive.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Scientific, Inc. (“Semler Scientific”), respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company’s future financial performance, the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such statements are often characterized by the use of qualified words (and their derivatives) such as “may,” “will,” “anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project,” “predict,” “potential,” “assume,” “forecast,” “target,” “budget,” “outlook,” “trend,” “guidance,” “objective,” “goal,” “strategy,” “opportunity,” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgments of Strive, Semler Scientific and/or their respective management teams about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements. Such risks, uncertainties and assumptions, include, among others, the following:

These factors are not necessarily all of the factors that could cause Strive’s, Semler Scientific’s or the combined company’s actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Strive, Semler Scientific or the combined company’s results.

Although each of Strive and Semler Scientific believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that the actual results of Strive or Semler Scientific will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Strive’s Quarterly Report on Form 10-Q filed on November 14, 2025, Strive's Form S-4 filed on October 10, 2025, Semler Scientific’s most recent Quarterly Report on Form 10-Q filed on November 12, 2025, and other documents subsequently filed by Strive and Semler Scientific with the SEC.

The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive, Semler Scientific or their respective businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Forward-looking statements contained in this press release speak only as of the date hereof, and Strive and Semler Scientific undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction, Strive has filed with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the Class A common stock to be issued by Strive in connection with the proposed transaction and that will include an information statement of Strive, proxy statement of Semler Scientific and a prospectus of Strive (the “Information Statement/Proxy Statement/Prospectus”), and each of Strive and Semler Scientific may file with the SEC any other relevant documents concerning the proposed transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Scientific to seek their approval of the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF SEMLER SCIENTIFIC ARE URGED TO READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STRIVE, SEMLER SCIENTIFIC AND THE PROPOSED TRANSACTION AND RELATED MATTERS.

A copy of the Registration Statement, Information Statement/Proxy Statement/Prospectus, as well as other filings containing information about Strive and Semler Scientific, may be obtained, free of charge, at the SEC’s website (http://www.sec.gov). You will also be able to obtain these documents, when they are filed, free of charge, from Strive by accessing Strive’s website at https://investors.strive.com/. Copies of the Registration Statement, the Information Statement/Proxy Statement/Prospectus and the filings with the SEC that will be incorporated by reference therein can also be obtained, without charge, by directing a request to Strive’s Investor Relations department at 200 Crescent Court, Suite 1400, Dallas, Texas 75201 or by calling (855) 427-7360 or by submitting an inquiry at https://investors.strive.com/ir-resources/contact-ir. Copies of the documents filed with the SEC by Semler Scientific will be available free of charge on Semler Scientific’s website at https://ir.semlerscientific.com/. The information on Strive’s or Semler Scientific’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

Participants in the Solicitation

Strive, Semler Scientific and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Semler Scientific in connection with the proposed transaction. Information about the interests of the directors and executive officers of Strive and Semler Scientific and other persons who may be deemed to be participants in the solicitation of stockholders of Semler Scientific in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Information Statement/Proxy Statement/Prospectus related to the proposed transaction, which will be filed with the SEC. Information about the current directors and executive officers of Semler Scientific, and their ownership of Semler Scientific common stock is set forth in the section entitled “THE MERGERS” and “SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT” included in Strive's Form S-4 filed with the SEC on October 10, 2025 and Semler Scientific's Current Report on Form 8-K filed with the SEC on October 17, 2025. Additional information regarding ownership of Semler Scientific’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001554859. Information about the directors and executive officers of Strive is contained in Strive’s Current Report on Form 8-K filed with the SEC on September 15, 2025, Strive’s Current Report on Form 8-K filed with the SEC on October 6, 2025 and under “Meet the Leadership Team” accessed through the “About Us” link on Strive’s website at https://strive.com/team. Additional information regarding ownership of Strive’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4 which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=1920406. These documents and the other SEC filings described in this paragraph may be obtained free of charge as described above under the heading “Additional Information and Where to Find It.”

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.


Primary Logo